Actelion Grows Its PAH Franchise With Uptravi Approval
Executive Summary
Broad label for oral product could help Actelion weather the loss of Tracleer to generic competition.
You may also be interested in...
Actelion’s Opsumit Ramps Up As Tracleer Patent Loss Gets Closer
The Swiss biotech’s top-selling product Tracleer still accounts for 75% of its sales but Actelion has a strategy that includes launching new PAH therapies and developing a specialty pharma pipeline to cope with the upcoming loss of patent protection.
Rising's Generic Price Fixing Settlement Follows Bankruptcy, Cooperation
Rising Pharmaceuticals agrees to pay $3.1m, admits to conspiring to fix prices for hypertension drug, and enters into deferred prosecution agreement. Pfizer asks court to be removed from complaint by state AGs.
Innovative Trial Designs Are 'Life And Death Matter' For Pharma, Amgen Tells US FDA
Amgen exec calls for more informal agency feedback and alignment between review divisions in understanding design methodologies.
Existing Subscriber?
Sign in to continue reading.
Need a specific report? 1000+ reports available
Buy Reports
Need a specific report? 1000+ reports available
Buy Reports